Barclays
DMTX

Barclays’s Dimension Therapeutics, Inc DMTX Stock Holding History

Barclays’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,809
Closed -$8K – 7344
2017
Q2 		$8K Sell
5,809
-2,282
-28% -$3.1K ﹤0.01% 6137
2017
Q1 		$14K Buy
8,091
+7,880
+3,735% +$20.9K ﹤0.01% 5971
2016
Q4 		$1K Buy
211
+134
+174% +$713 ﹤0.01% 6566
2016
Q3 		$1K Buy
+77
New +$557 ﹤0.01% 6568

Other funds holding DMTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Barclays's DMTX Position: Q3 2017 in Review

Barclays sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 5,809 shares — an estimated $8K sold.

Barclays first reported a position in DMTX in Q3 2016 and held it in 4 quarters. The position peaked at $14K in Q1 2017. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

  • Barclays reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Barclays sold 5,809 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $8K.
  • Barclays first reported a position in Dimension Therapeutics, Inc in Q3 2016 and held it in 4 quarters.
  • Barclays's Dimension Therapeutics, Inc position peaked at $14K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.